Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Equity Average: 2020-2025

Historic Equity Average for Harmony Biosciences Holdings (HRMY) over the last 5 years, with Sep 2025 value amounting to $804.1 million.

  • Harmony Biosciences Holdings' Equity Average rose 41.64% to $804.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $804.1 million, marking a year-over-year increase of 41.64%. This contributed to the annual value of $563.1 million for FY2024, which is 29.47% up from last year.
  • Harmony Biosciences Holdings' Equity Average amounted to $804.1 million in Q3 2025, which was up 7.67% from $746.8 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Equity Average ranged from a high of $804.1 million in Q3 2025 and a low of $102.5 million during Q1 2021.
  • For the 3-year period, Harmony Biosciences Holdings' Equity Average averaged around $572.6 million, with its median value being $527.0 million (2024).
  • Data for Harmony Biosciences Holdings' Equity Average shows a peak YoY soared of 120.58% (in 2022) over the last 5 years.
  • Over the past 5 years, Harmony Biosciences Holdings' Equity Average (Quarterly) stood at $169.3 million in 2021, then skyrocketed by 120.58% to $373.4 million in 2022, then climbed by 27.00% to $474.2 million in 2023, then soared by 32.44% to $628.0 million in 2024, then surged by 41.64% to $804.1 million in 2025.
  • Its last three reported values are $804.1 million in Q3 2025, $746.8 million for Q2 2025, and $689.8 million during Q1 2025.